April 25, 2022
The pharmaceutical firm Pfizer has voluntary recalled a blood stress treatment for the second time in a month.
Pfizer is recalling 5 a lot of blood stress medication Accupril due to elevated ranges of a nitrosamine, Nnitroso-quinapril, the corporate stated in a information launch posted Friday on the FDA web site.
Nitrosamines are present in water and meals, together with grilled meats and dairy merchandise, however impurities could improve an individual’s most cancers threat over lengthy durations of time, Pfizer stated.
Accupril is used to decrease blood stress and handle coronary heart failure. Pfizer stated it has not obtained any studies of antagonistic reactions by folks taking the drug.
“Pfizer believes the profit/threat profile of the merchandise stays constructive primarily based on at present obtainable knowledge. Though long-term ingestion of Nnitroso-quinapril could also be related to a possible elevated most cancers threat in people, there is no such thing as a quick threat to sufferers taking this treatment,” the corporate stated.
The Accupril tables are offered in 10-, 20- and 40-mg doses. The affected lot numbers are DR9639, DX8682, DG1188, DX6031, and CK6260.
Sufferers taking the product ought to speak to their physician. Sufferers with the affected product ought to name 888-345-0481.
Pfizer recalled one other blood stress treatment on March 22.
The affected merchandise in that recall are quinapril HCl/hydrochlorothiazide (Accuretic) tablets that Pfizer distributes, and two approved generics, quinapril plus hydrochlorothiazide and quinapril HCl/hydrochlorothiazide, distributed by Greenstone. The recall is over increased than accepted ranges of N-nitroso-quinapril, a compound often called a nitrosamine.